Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK rearrangement
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK inhibitor
Sensitive: A2 - Guideline
ALK inhibitor
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
brigatinib
Sensitive: A2 - Guideline
brigatinib
Sensitive
:
A2
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ceritinib
Sensitive: B - Late Trials
ceritinib
Sensitive
:
B
ceritinib
Sensitive: B - Late Trials
ceritinib
Sensitive
:
B
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
nivolumab
Sensitive: C2 – Inclusion Criteria
nivolumab
Sensitive
:
C2
nivolumab
Sensitive: C2 – Inclusion Criteria
nivolumab
Sensitive
:
C2
ALK rearrangement
Solid Tumor
ALK rearrangement
Solid Tumor
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive: C2 – Inclusion Criteria
crizotinib
Sensitive
:
C2
crizotinib
Sensitive: C2 – Inclusion Criteria
crizotinib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ceritinib + ribociclib
Sensitive: C2 – Inclusion Criteria
ceritinib + ribociclib
Sensitive
:
C2
ceritinib + ribociclib
Sensitive: C2 – Inclusion Criteria
ceritinib + ribociclib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
durvalumab
Sensitive: C2 – Inclusion Criteria
durvalumab
Sensitive
:
C2
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab + atezolizumab
Sensitive
:
C2
bevacizumab + atezolizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab + atezolizumab
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
bevacizumab + crizotinib
Sensitive: C3 – Early Trials
bevacizumab + crizotinib
Sensitive
:
C3
bevacizumab + crizotinib
Sensitive: C3 – Early Trials
bevacizumab + crizotinib
Sensitive
:
C3
ALK rearrangement
Lung Adenocarcinoma
ALK rearrangement
Lung Adenocarcinoma
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 inhibitor
Resistant
:
C3
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 inhibitor
Resistant
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
ALK rearrangement
Non-Hodgkin’s Lymphoma
ALK rearrangement
Non-Hodgkin’s Lymphoma
ceritinib
Sensitive: C3 – Early Trials
ceritinib
Sensitive
:
C3
ceritinib
Sensitive: C3 – Early Trials
ceritinib
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
IPI-504
Sensitive: C3 – Early Trials
IPI-504
Sensitive
:
C3
IPI-504
Sensitive: C3 – Early Trials
IPI-504
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK inhibitor
Sensitive: C3 – Early Trials
ALK inhibitor
Sensitive
:
C3
ALK inhibitor
Sensitive: C3 – Early Trials
ALK inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
WX-0593
Sensitive: C3 – Early Trials
WX-0593
Sensitive
:
C3
WX-0593
Sensitive: C3 – Early Trials
WX-0593
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
atezolizumab
Sensitive: C3 – Early Trials
atezolizumab
Sensitive
:
C3
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK rearrangement
Renal Cell Carcinoma
ALK rearrangement
Renal Cell Carcinoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
ALK rearrangement
Sarcoma
ALK rearrangement
Sarcoma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
ALK rearrangement
Lung Adenocarcinoma
ALK rearrangement
Lung Adenocarcinoma
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
crizotinib
Resistant: C4 – Case Studies
crizotinib
Resistant
:
C4
ALK rearrangement
Lung Adenocarcinoma
ALK rearrangement
Lung Adenocarcinoma
bevacizumab
Sensitive: C4 – Case Studies
bevacizumab
Sensitive
:
C4
bevacizumab
Sensitive: C4 – Case Studies
bevacizumab
Sensitive
:
C4
ALK rearrangement
Renal Cell Carcinoma
ALK rearrangement
Renal Cell Carcinoma
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login